These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
159 related articles for article (PubMed ID: 36900378)
1. ImmunoPET Imaging Identifies the Optimal Timepoint for Combination Therapy in Xenograft Models of Triple-Negative Breast Cancer. Li Z; Belitzky E; Blaha O; Cavaliere A; Katz SR; Aboian M; Melegari L; Rajabimoghadam K; Kurpiewski S; Zhu X; Marquez-Nostra B Cancers (Basel); 2023 Mar; 15(5):. PubMed ID: 36900378 [TBL] [Abstract][Full Text] [Related]
2. Preclinical PET imaging of glycoprotein non-metastatic melanoma B in triple negative breast cancer: feasibility of an antibody-based companion diagnostic agent. Marquez-Nostra BV; Lee S; Laforest R; Vitale L; Nie X; Hyrc K; Keler T; Hawthorne T; Hoog J; Li S; Dehdashti F; Ma CX; Lapi SE Oncotarget; 2017 Nov; 8(61):104303-104314. PubMed ID: 29262642 [TBL] [Abstract][Full Text] [Related]
3. [89Zr]ZrDFO-CR011 PET Correlates with Response to Glycoprotein Nonmetastatic Melanoma B-targeted Therapy in Triple-negative Breast Cancer. Lee S; Cavaliere A; Gallezot JD; Keler T; Michelhaugh SK; Belitzky E; Liu M; Mulnix T; Maher SE; Bothwell ALM; Li F; Phadke M; Mittal S; Marquez-Nostra B Mol Cancer Ther; 2022 Mar; 21(3):440-447. PubMed ID: 35027482 [TBL] [Abstract][Full Text] [Related]
4. Cetuximab PET delineated changes in cellular distribution of EGFR upon dasatinib treatment in triple negative breast cancer. McKnight BN; Kim S; Boerner JL; Viola NT Breast Cancer Res; 2020 Apr; 22(1):37. PubMed ID: 32295603 [TBL] [Abstract][Full Text] [Related]
5. Development of [ Cavaliere A; Sun S; Lee S; Bodner J; Li Z; Huang Y; Moores SL; Marquez-Nostra B Eur J Nucl Med Mol Imaging; 2021 Feb; 48(2):383-394. PubMed ID: 32770372 [TBL] [Abstract][Full Text] [Related]
7. Monitoring Src status after dasatinib treatment in HER2+ breast cancer with McKnight BN; Viola-Villegas NT Breast Cancer Res; 2018 Oct; 20(1):130. PubMed ID: 30359299 [TBL] [Abstract][Full Text] [Related]
8. Preclinical evaluation of the theranostic potential of Wu Y; Li T; Zhang X; Jing H; Li F; Huo L EJNMMI Radiopharm Chem; 2024 Jan; 9(1):5. PubMed ID: 38194043 [TBL] [Abstract][Full Text] [Related]
9. Positron-Emission Tomography of HER2-Positive Breast Cancer Xenografts in Mice with Al-Saden N; Lam K; Chan C; Reilly RM Mol Pharm; 2018 Aug; 15(8):3383-3393. PubMed ID: 29957952 [TBL] [Abstract][Full Text] [Related]
10. Tumor uptake and tumor/blood ratios for [ Al-Saden N; Cai Z; Reilly RM Nucl Med Biol; 2018 Dec; 67():43-51. PubMed ID: 30390575 [TBL] [Abstract][Full Text] [Related]
11. [ Massicano AVF; Song PN; Mansur A; White SL; Sorace AG; Lapi SE Cancers (Basel); 2023 May; 15(10):. PubMed ID: 37345044 [TBL] [Abstract][Full Text] [Related]
12. Excellent effects and possible mechanisms of action of a new antibody-drug conjugate against EGFR-positive triple-negative breast cancer. Zhou DD; Bai WQ; Zhai XT; Sun LP; Zhen YS; Li ZR; Miao QF Mil Med Res; 2021 Dec; 8(1):63. PubMed ID: 34879870 [TBL] [Abstract][Full Text] [Related]
13. [ Lu Y; Li M; Massicano AVF; Song PN; Mansur A; Heinzman KA; Larimer BM; Lapi SE; Sorace AG Molecules; 2021 Mar; 26(6):. PubMed ID: 33809310 [TBL] [Abstract][Full Text] [Related]
15. Glycoprotein non-metastatic b (GPNMB): A metastatic mediator and emerging therapeutic target in cancer. Maric G; Rose AA; Annis MG; Siegel PM Onco Targets Ther; 2013; 6():839-52. PubMed ID: 23874106 [TBL] [Abstract][Full Text] [Related]
16. Liu H; Sun H; Zhang B; Liu S; Deng S; Weng Z; Zuo B; Yang J; He Y Breast Cancer; 2020 May; 27(3):372-380. PubMed ID: 31781983 [TBL] [Abstract][Full Text] [Related]
17. Preclinical Evaluation of an Engineered Single-Chain Fragment Variable-Fragment Crystallizable Targeting Human CD44. Diebolder P; Mpoy C; Scott J; Huynh TT; Fields R; Spitzer D; Bandara N; Rogers BE J Nucl Med; 2021 Jan; 62(1):137-143. PubMed ID: 32513906 [TBL] [Abstract][Full Text] [Related]
18. Noninvasive Classification of Human Triple Negative Breast Cancer by PET Imaging with GRP78-Targeted Molecular Probe [ Zhao H; Meng H; Wen J; Wang C; Liu J; Huang G Mol Imaging Biol; 2020 Jun; 22(3):772-779. PubMed ID: 31452065 [TBL] [Abstract][Full Text] [Related]
19. EMERGE: A Randomized Phase II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Advanced Glycoprotein NMB-Expressing Breast Cancer. Yardley DA; Weaver R; Melisko ME; Saleh MN; Arena FP; Forero A; Cigler T; Stopeck A; Citrin D; Oliff I; Bechhold R; Loutfi R; Garcia AA; Cruickshank S; Crowley E; Green J; Hawthorne T; Yellin MJ; Davis TA; Vahdat LT J Clin Oncol; 2015 May; 33(14):1609-19. PubMed ID: 25847941 [TBL] [Abstract][Full Text] [Related]